Stock Screener App

Frei -

Installieren

Drug Manufacturers - Major

65.35

1.41% 0.91

after-market

Handel nachbörslich: 65.96 0.61 +0.93%

Astrazeneca PLC (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Astrazeneca PLC Aktie (AZN) Neueste Nachrichten

Why Astrazeneca (AZN) Outpaced the Stock Market Today - Yahoo Finance

Analysts are saying the AstraZeneca share price looks cheap despite China turmoil - MSN

AstraZeneca takes advantage of Tanium’s integrations with Microsoft & ServiceNow - Tech Monitor

Beijing Woos AstraZeneca for Investment While Probe Continues - BNN Bloomberg

AstraZeneca PLC ADR falls Thursday, underperforms market - MarketWatch

AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman - GlobeNewswire

AstraZeneca outperforms market despite losses on the day - MarketWatch

AstraZeneca PLC Announcement: If You Have Suffered Losses - GlobeNewswire

AstraZeneca strengthens global operations despite China challenges - IG

AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch

AstraZeneca falls Wednesday, underperforms market - MarketWatch

Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexif - Quantisnow

AstraZeneca insiders expect sales dip in China after arrest of local boss - Financial Times

Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action InvestigationAZN - Morningstar

AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch

Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey

AstraZeneca is expanding in Cambridge as it plans to grow Mass. presence - The Business Journals

Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN - Business Wire

AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch

AstraZeneca rises Monday, outperforms market - MarketWatch

AstraZeneca's SWOT analysis: oncology giant's stock poised for growth - Investing.com

AstraZeneca announces board refresh with new directors - Investing.com

AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November - MarketBeat

AstraZeneca goes cheap – should you buy? - MoneyWeek

AstraZeneca: two appointments to the Board of Directors - Marketscreener.com

AstraZeneca Strengthens Board with New Non-Executive Director Appointments - TipRanks

AstrazenecaPotential Approval For Soliris Would Mark First An… - Marketscreener.com

AstraZeneca names new non-executive directors - Investing.com

AstraZeneca Strengthens Leadership with New Appointments - Devdiscourse

3 Unstoppable Stocks to Buy Right Now - The Motley Fool

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp - MarketBeat

Peapack Gladstone Financial Corp Grows Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Verition Fund Management LLC Has $338,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response - Citeline News & Insights

AstraZeneca PLC ADR underperforms Friday when compared to competitors - MarketWatch

AstraZeneca falls Friday, underperforms market - MarketWatch

AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Franklin Resources Inc. - MarketBeat

Wilmington Savings Fund Society FSB Buys New Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Vestcor Inc Has $1.02 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Hutchmed to get Takeda milestone payment - Marketscreener.com

AstraZeneca ups job losses to 7,600 as cuts costs - Reuters

AstraZeneca Partners with Tracer Bio for Revolutionary Cancer Monitoring Technology - StockTitan

AstraZeneca’s Anna Berg Asberg on Scaling Generative AI at AI Summit New York - IoT World Today

AstraZeneca rises Thursday, outperforms market - MarketWatch

Virtu Financial LLC Purchases New Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

AstraZeneca: Lynparza shows promise in breast cancer - Marketscreener.com

Pitavastatin Market Key Players AnalysisPfizer Inc., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc. - openPR

AstraZeneca Sees Bright Future For Registry-Based Randomized Clinical Trials - News & Insights

AstraZeneca PLC ADR rises Wednesday, still underperforms market - MarketWatch

AstraZeneca, Merck report positive long-term data for Lynparza - MSN

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients - Yahoo Finance

AstraZeneca, Merck report positive long-term data for Lynparza (NASDAQ:AZN) - Seeking Alpha

AstraZeneca rises Wednesday, still underperforms market - MarketWatch

Teachers Retirement System of The State of Kentucky Reduces Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Opinion: Don’t start with technology. Start with the patient - Devex

National Bank of Canada FI Has $12.34 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

AstraZeneca PLC (LON:AZN) Receives £104.12 Consensus Target Price from Brokerages - MarketBeat

AstraZeneca PLC ADR falls Tuesday, underperforms market - MarketWatch

AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China - Yahoo Finance

AstraZeneca falls Tuesday, underperforms market - MarketWatch

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term - Yahoo Finance

Groupama Asset Managment Grows Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters